Zevra beefs up rare disease portfolio via $91M acquisition of Acer Therapeutics

Zevra Ther­a­peu­tics is set to buy Ac­er Ther­a­peu­tics in a deal worth up to $91 mil­lion, which finds the Flori­da-head­quar­tered biotech with an ad­di­tion­al two as­sets.

As a part of the deal, Zevra will ab­sorb Ac­er’s urea cy­cle dis­or­der treat­ment Ol­pru­va (sodi­um phenyl­bu­tyrate), which se­cured an FDA ap­proval in De­cem­ber last year, as well as be­ta-block­er celipro­lol, which is in a Phase III vas­cu­lar Ehlers-Dan­los syn­drome tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.